A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL

Phase 1/2 Completed 36 enrolled Eli Lilly and Company

RandomizedParallel-groupOpen-labelTreatment

Summary

The main purpose of this study is to evaluate the safety of the study drug known as LY3039478 in combination with dexamethasone in participants with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma (T-ALL/T-LBL).

Timeline

Start: 2015-10-01
Primary completion: 2018-01-15
Completion: 2018-01-15

Publications

Borthakur G, Martinelli G, Raffoux E, Chevallier P, Chromik J, Lithio A, Smith CL, Yuen E, Oakley GJ 3rd, Benhadji KA, DeAngelo DJ. Phase 1 study to evaluate Crenigacestat (LY3039478) in combination with dexamethasone in patients with T-cell acute lymphoblastic leukemia and lymphoma. Cancer. 2021 Feb 1;127(3):372-380. doi: 10.1002/cncr.33188. Epub 2020 Oct 27.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	crenigacestat	Small molecule	50 mg	Oral
Subject	crenigacestat	Small molecule	75 mg	Oral
Subject	crenigacestat	Small molecule	100 mg	Oral
Subject	crenigacestat	Small molecule	125 mg	Oral
Background	Dexamethasone	Small molecule	24 mg	Oral

A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL

Summary

Timeline

Publications

Drugs

Indications